- Home
- RILYP vs CMMB Comparison
RILYP vs CMMB Comparison
Compare RILYP & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RILYP
- CMMB
- Stock Information
- Founded
- RILYP 1973
- CMMB 2004
- Country
- RILYP United States
- CMMB Israel
- Employees
- RILYP 2383
- CMMB N/A
- Industry
- RILYP Investment Managers
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- RILYP Finance
- CMMB Health Care
- Exchange
- RILYP Nasdaq
- CMMB Nasdaq
- Market Cap
- RILYP N/A
- CMMB 23.6M
- IPO Year
- RILYP N/A
- CMMB N/A
- Fundamental
- Price
- RILYP $4.01
- CMMB $1.39
- Analyst Decision
- RILYP
- CMMB Strong Buy
- Analyst Count
- RILYP 0
- CMMB 2
- Target Price
- RILYP N/A
- CMMB $9.00
- AVG Volume (30 Days)
- RILYP 20.5K
- CMMB 863.6K
- Earning Date
- RILYP 01-01-0001
- CMMB 03-03-2025
- Dividend Yield
- RILYP 30.91%
- CMMB N/A
- EPS Growth
- RILYP N/A
- CMMB N/A
- EPS
- RILYP N/A
- CMMB N/A
- Revenue
- RILYP $854,383,000.00
- CMMB N/A
- Revenue This Year
- RILYP N/A
- CMMB N/A
- Revenue Next Year
- RILYP N/A
- CMMB N/A
- P/E Ratio
- RILYP N/A
- CMMB N/A
- Revenue Growth
- RILYP N/A
- CMMB N/A
- 52 Week Low
- RILYP $3.28
- CMMB $0.58
- 52 Week High
- RILYP $20.49
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- RILYP 39.50
- CMMB 38.56
- Support Level
- RILYP $3.84
- CMMB $1.21
- Resistance Level
- RILYP $4.93
- CMMB $1.54
- Average True Range (ATR)
- RILYP 0.79
- CMMB 0.16
- MACD
- RILYP -0.07
- CMMB -0.01
- Stochastic Oscillator
- RILYP 5.45
- CMMB 32.73
About RILYP B. Riley Financial Inc.
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.